Inovio Pharmaceuticals, Inc. (INO)
NASDAQ: INO · Real-Time Price · USD
1.750
-0.060 (-3.31%)
At close: Mar 26, 2025, 4:00 PM
1.770
+0.020 (1.14%)
After-hours: Mar 26, 2025, 7:40 PM EST

Inovio Pharmaceuticals Stock Forecast

INO's stock price has decreased by -85.89% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 5 analysts with 12-month price forecasts for Inovio Pharmaceuticals stock have an average target of 12.2, with a low estimate of 3.00 and a high estimate of 20. The average target predicts an increase of 597.14% from the current stock price of 1.75.

Analyst Consensus: Buy
Target Low Average Median High
Price $3.00 $12.2 $15 $20
Change +71.43% +597.14% +757.14% +1042.9%

Analyst Ratings

The average analyst rating for Inovio Pharmaceuticals stock from 5 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating Oct '24Nov '24Dec '24Jan '25Feb '25Mar '25
Strong Buy 000000
Buy 444443
Hold 222222
Sell 000000
Strong Sell 000000
Total 666665

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
RBC Capital
RBC Capital
Hold
Maintains
$6$5
Hold Maintains $6$5 +185.71% Mar 19, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Hold
Reiterates
$3
Hold Reiterates $3 +71.43% Mar 19, 2025
Citizens Capital Markets
Citizens Capital Markets
Buy
Reiterates
$18
Buy Reiterates $18 +928.57% Mar 14, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Hold
Maintains
$5$3
Hold Maintains $5$3 +71.43% Jan 13, 2025
JMP Securities
JMP Securities
Buy
Reiterates
$18
Buy Reiterates $18 +928.57% Jan 10, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
2.62M
from 217.76K
Increased by 1,105.02%
Revenue Next Year
26.83M
from 2.62M
Increased by 922.41%
EPS This Year
-2.63
from -3.95
EPS Next Year
-2.26
from -2.63
Fiscal Year FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 FY 2027
Period Ending Dec 31, 2020 Dec 31, 2021 Dec 31, 2022 Dec 31, 2023 Dec 31, 2024 Dec 31, 2025 Dec 31, 2026 Dec 31, 2027
Revenue
7.41M1.77M10.26M832.01K217.76K2.62M26.83M78.00M
Revenue Growth
80.24%-76.05%478.24%-91.89%-73.83%1,105.02%922.41%190.73%
EPS
-12.87-17.45-14.07-6.09-3.95-2.63-2.26-1.41
EPS Growth
--------
Forward PE
--------
No. Analysts -----765
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 20252026202720282029
High 16.0M61.6M118.8M
Avg 2.6M26.8M78.0M
Low n/a9.7M47.7M

Revenue Growth

Revenue Growth 20252026202720282029
High
7,224.7%
2,247.3%
342.6%
Avg
1,105.0%
922.4%
190.7%
Low -
271.2%
77.9%

EPS Forecast

EPS 20252026202720282029
High -1.13-0.63-0.28
Avg -2.63-2.26-1.41
Low -4.36-3.34-2.46

EPS Growth

EPS Growth 20252026202720282029
High ---
Avg ---
Low ---
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.